MICROtransplant to refractory acute myeloid leukemia in Egyptian population. Issue 6 (November 2019)

• Record Type: Journal Article
• Authors: Emarah, Ziad; Shamaa, Sameh; El-Zaafarany, Maha; Eisa, Noha; Khalaf, Mohamed
• Is Part Of: Current opinion in hematology. Volume 26:Issue 6(2019:Nov.)
• Publication Date: 2019-11
• Subjects: cellular immunotherapy -- haploidentical -- microtransplantation; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1097/MOH.0000000000000547
• Languages: English
• ISSNs: 1065-6251

Abstract

Abstract : Purpose of review: The purpose of this review is to outline Egyptian experience of nonengraftment haploidentical cellular therapy [microtransplantation (MST)] for patients with refractory acute myeloid leukemia. Recent findings: The use of granulocyte colony-stimulating factor primed halo-identical MST appears to be a biologically active therapy in patients with refractory acute myeloid leukemia (AML), especially in patients received less than four previous chemotherapy lines, fludarabine-free previous chemotherapy, response naïve and young age patients. Summary: Refractory AML is still challenging. MST is promising, however the optimum conditioning, stem-cell dose, matching degree are factors should be optimized.